Markets:

Overview

News

Currencies

International

Treasuries

Becton Dickinson (NY:BDX)

162.85 -1.03 (-0.63%)

Streaming Delayed Price Updated: 2:10 PM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Becton Dickinson

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

BD Bolsters Portfolio With $4.2B Cash Deal For Edwards Lifesciences' Critical Care Group: Details ↗

June 03, 2024

BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition enhances BD's portfolio with advanced AI-enabled monitoring...

Via Benzinga

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal ↗

June 03, 2024

Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion.

Via Investor's Business Daily

Trade Winds Turning: 3 Stocks Poised to Gain from Biden’s China Tariffs ↗

May 21, 2024

Here are three potential stocks to buy that could benefit from China tariffs amidst the turning trade winds.

Via InvestorPlace

Topics World Trade

Biden's New Tariffs On Chinese Imports Are A 'Clear Giveaway' To These Two Tesla Rivals, Jim Cramer Says: 'I Like This Policy' ↗

May 15, 2024

Jim Cramer has highlighted the potential benefits for U.S. automakers, particularly Ford and General Motors, following the Biden administration's decision to impose substantial tariffs on Chinese...

Via Benzinga

Topics World Trade

Looking Into Becton Dickinson's Recent Short Interest ↗

April 29, 2024

Via Benzinga

Peering Into Becton Dickinson's Recent Short Interest ↗

March 29, 2024

Via Benzinga

Peering Into Becton Dickinson's Recent Short Interest ↗

February 21, 2024

Via Benzinga

Becton Dickinson Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

February 05, 2024

Via Benzinga

MarketBeat Week in Review – 4/29 - 5/3

May 04, 2024

Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024

Via MarketBeat

Topics Economy Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

May 03, 2024

Via Benzinga

Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook ↗

May 02, 2024

BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX...

Via Benzinga

BDX Stock Earnings: Becton, Dickinson Beats EPS, Beats Revenue for Q2 2024 ↗

May 02, 2024

BDX stock results show that Becton, Dickinson beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Earnings Preview For Becton, Dickinson ↗

January 31, 2024

Via Benzinga

Boston Scientific Bucks the Medtech Slow Down and Raises Outlook

April 30, 2024

Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook.

Via MarketBeat

How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025? ↗

April 26, 2024

Curious to know how much these dividend aristocrats could grow in the next year? Here's the answer for several well-known shares.

Via InvestorPlace

Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows ↗

April 03, 2024

Want quality picks and reliable income at a discount? Check out these Dividend Aristocrats trading at 52-week lows.

Via InvestorPlace

AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement ↗

April 02, 2024

AngioDynamics resolves decade-long patent litigation with Becton, Dickinson in landmark settlement, streamlining legal expenses and marking a significant milestone for the company.

Via Benzinga

Topics Intellectual Property

Should You Buy Solventum (SOLV) Stock After the 3M Spinoff? ↗

April 01, 2024

Although 3M shareholders have reason to dump the Solventum spinoff, SOLV stock could be intriguing at the right price.

Via InvestorPlace

Jim Cramer Says Don't Sell This Beauty Brand, Believes KKR And Blackstone 'Can Make More Money' ↗

March 26, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer sang the praises of Energy Transfer LP (NYSE: ET), which posted better-than-expected earnings

Via Benzinga

Becton, Dickinson And Co. Dividend Stock Analysis ↗

March 23, 2024

Becton, Dickinson, and Co. provides a wide range of medical devices and diagnostic products used in hospitals, doctors' offices, research labs, and other settings.

Via Talk Markets

FDA Probe On China-Made Syringes: Becton Dickinson Boosts US Syringe Output Following Concerns ↗

March 21, 2024

BD boosts U.S. production of medical syringes following FDA concerns over Chinese-made syringes. Learn how BD addresses patient care continuity amid ongoing quality probe.

Via Benzinga

10 Big-Name Stocks Near 52-Week Lows: Are They A Buy? ↗

March 16, 2024

Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...

Via Talk Markets

7 Robotic Surgery Stocks to Buy for the Future of Healthcare ↗

March 13, 2024

Discover seven robotic surgery stocks primed for growth as the industry evolves. Unveil opportunities in a market set to double by 2033.

Via InvestorPlace

3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March ↗

March 11, 2024

These are some of the best-performing stocks in what's arguably society's most important industry.

Via The Motley Fool

3 Stocks to Buy at 52-Week Lows: March 4 Edition ↗

March 04, 2024

Sometimes a gem can get tossed in the trash, which is what you will find with these three stocks to buy at 52-week lows.

Via InvestorPlace

Get Paid While You Wait: 7 Dividend Aristocrats to Buy Now ↗

February 27, 2024

Worried about an upcoming market correction? These seven Dividend Aristocrats are a safe harbor which offer great income streams.

Via InvestorPlace

Medical Device Maker Becton Dickinson's Q1 Earnings: Here's Why This Analyst Is Bullish On Long-Term Prospects ↗

February 01, 2024

BD exceeds expectations with Q1 2024 adjusted EPS of $2.68 (vs $2.40 consensus). William Blair maintains a positive outlook, confident in BD's progress towards its 2025.

Via Benzinga

Earnings Scheduled For February 1, 2024 ↗

February 01, 2024

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...

Via Benzinga

Biotech And Medtech Portfolio Notes On A Fed Day ↗

January 31, 2024

The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%

Via Talk Markets

Topics Economy

Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst ↗

January 23, 2024

Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.